INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 429m ago
HOUSE PTR29m ago
SEC 13F29m ago
ROBINHOOD CHAIN28m ago
Corporate insider
HB

Hohl Benjamin

CHIEF FINANCIAL OFFICERCIK 0001882764

EDGAR filingsOpen in network
Disclosed transactions17
Buys / sells0 / 9
Max Insider Score21
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
0
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
6,018 sh
Oct 19, 2026Oct 21, 2026
traded Oct 19, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Enliven Therapeutics, Inc.CHIEF FINANCIAL OFFICER · Dec 23, 2025
0
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Option exercise · 10b5-1 plan
M
$89K
6,018 sh
Oct 19, 2026
Oct 21, 2026
traded Oct 19, 2026
+2d
SEC FORM 4

Evidence

10
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$232K
6,018 sh
Oct 19, 2026Oct 21, 2026
traded Oct 19, 2026
+2dSEC FORM 4

Evidence

0
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
3,982 sh
Sep 17, 2026Sep 21, 2026
traded Sep 17, 2026
+4dSEC FORM 4

Evidence

13
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$111K
2,194 sh
Sep 17, 2026Sep 21, 2026
traded Sep 17, 2026
+4dSEC FORM 4

Evidence

6
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$15K
289 sh
Sep 17, 2026Sep 21, 2026
traded Sep 17, 2026
+4dSEC FORM 4

Evidence

2
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$59K
3,982 sh
Sep 17, 2026Sep 21, 2026
traded Sep 17, 2026
+4dSEC FORM 4

Evidence

13
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$177K
3,535 sh
Sep 17, 2026Sep 21, 2026
traded Sep 17, 2026
+4dSEC FORM 4

Evidence

4
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$82K
1,388 sh
Aug 17, 2026Aug 19, 2026
traded Aug 17, 2026
+2dSEC FORM 4

Evidence

11
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$270K
4,630 sh
Aug 17, 2026Aug 19, 2026
traded Aug 17, 2026
+2dSEC FORM 4

Evidence

9
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$15K
6,018 sh
Jun 17, 2026Jun 22, 2026
traded Jun 17, 2026
+5dSEC FORM 4

Evidence

14
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$59K
1,379 sh
Jun 17, 2026Jun 22, 2026
traded Jun 17, 2026
+5dSEC FORM 4

Evidence

18
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$149K
3,401 sh
Jun 17, 2026Jun 22, 2026
traded Jun 17, 2026
+5dSEC FORM 4

Evidence

14
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$55K
1,238 sh
Jun 17, 2026Jun 22, 2026
traded Jun 17, 2026
+5dSEC FORM 4

Evidence

9
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
6,018 sh
Jun 17, 2026Jun 22, 2026
traded Jun 17, 2026
+5dSEC FORM 4

Evidence

21
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Option exercise
M$32K
13.0K sh
Dec 22, 2025Dec 23, 2025
traded Dec 22, 2025
+1dSEC FORM 4

Evidence

13
HB
Hohl BenjaminCHIEF FINANCIAL OFFICER
ELVNEnliven Therapeutics, Inc.
Option exercise
M—
13.0K sh
Dec 22, 2025Dec 23, 2025
traded Dec 22, 2025
+1dSEC FORM 4

Evidence